CCBasic Materials · Specialty ChemicalsThe 10 Wall Street analysts covering The Chemours Co. hold a median 12-month price target of $16 — +24.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 55 of 100 as at 24 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores The Chemours Co. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (90): Reported profit is backed by cash, and the company is not expanding recklessly.
Revisions (30): Analysts have, on balance, been cutting their forecasts.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on CC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +24.9% from it.
Of the 20 most recent actions, 0 moved their price target up and 10 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 20 Oct 2026 | Truist Securities | Maintains | Buy | $24 → $20 |
| 14 Oct 2026 | Mizuho | Downgrade | Neutral | $18 → $15 |
| 13 Oct 2026 | Barclays | Initiates | Equal-Weight | $16 |
| 5 Oct 2026 | UBS | Maintains | Neutral | $18 → $16 |
| 5 Oct 2026 | UBS | Maintains | Neutral | — |
| 30 Sept 2026 | Mizuho | Maintains | Outperform | — |
| 30 Sept 2026 | Mizuho | Maintains | Outperform | $20 → $18 |
| 13 Aug 2026 | BMO Capital | Maintains | Outperform | — |
| 13 Aug 2026 | BMO Capital | Maintains | Outperform | $26 → $18 |
| 13 Aug 2026 | JP Morgan | Maintains | Neutral | $22 → $15 |
| 13 Aug 2026 | JP Morgan | Maintains | Neutral | — |
| 10 Aug 2026 | UBS | Downgrade | Neutral | $29 → $18 |
| 10 Aug 2026 | UBS | Downgrade | Neutral | — |
| 6 Aug 2026 | RBC Capital | Maintains | Outperform | — |
| 6 Aug 2026 | RBC Capital | Maintains | Outperform | $26 → $22 |
| 6 Aug 2026 | Truist Securities | Maintains | Buy | $30 → $24 |
| 6 Aug 2026 | Truist Securities | Maintains | Buy | — |
| 1 July 2026 | Mizuho | Maintains | Outperform | — |
| 1 July 2026 | Mizuho | Maintains | Outperform | $30 → $25 |
| 21 May 2026 | JP Morgan | Maintains | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
CC appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 23 Oct 2026, The Chemours Co. returned −5.7% against +14.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 10% of US stocks
Cheaper than 86% of US stocks
Cheaper than 99% of US stocks
Cheaper than 34% of US stocks
Higher than 25% of US stocks
Higher than 35% of US stocks
Higher than 18% of US stocks
Higher than 47% of US stocks
Higher than 24% of US stocks
Higher than 5% of US stocks
Higher than 54% of US stocks
Higher than 84% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
The Chemours Co. has a market value of $1.9B and an enterprise value of $5.4B.
Revenue in the twelve months to 30 June 2026: $5.8B. The latest quarter shrank 1.5% year on year.
Net income over the same four quarters: −$305.0M, a −5.3% net margin.
Free cash flow in the twelve months to 30 June 2026: $218.0M.
The Chemours Co. spent $54.0M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 67.8×; forward P/E: 6.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 2.75%, paying out 1667% of earnings.
The Chemours Co. employs 5,700 people — $1.0M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own The Chemours Co. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Chemours announced it expects to release its third-quarter 2026 financial results after market close on Monday, November 2, 2026.
Why it matters — CC watchers can note the scheduled date for the company's third-quarter results.
Robbins LLP said a class action was filed on behalf of investors who acquired Chemours securities from February 20 through August 4, 2026. The firm is urging investors with large losses to contact it for information about their rights.
Why it matters — The announcement concerns a class action involving CC securities and may be relevant to investors who held the stock during the stated period.
The 10 Wall Street analysts covering The Chemours Co. have a median 12-month price target of $16, with estimates ranging from $14 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 10 analysts covering The Chemours Co., 2 rate it a Buy, 8 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks The Chemours Co. 55 out of 100 across roughly 4,600 US stocks as at 24 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 24 Oct 2026, The Chemours Co. ranks 55 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (90 of 100).
No one can know that. What the data says: the median 12-month target from 10 analysts implies +24.9% from the last close, and Ticker Nerd's factor model ranks The Chemours Co. 55 out of 100 as at 24 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering The Chemours Co. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $20 over the next 12 months.
The Chemours Co. returned -5.7% over the 12 months to 23 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
The Chemours Company is a global chemistry company that develops and supplies industrial and specialty chemical products for a wide range of end markets. Its core business is organized into Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials, each serving distinct applications across refrigeration and air conditioning, coatings, plastics, transportation, semiconductors, electronics, and general industrial uses.
The most recent item we track (PRNewsWire, 21 Oct 2026): "Chemours Announces Dates for Third Quarter 2026 Earnings Release and Webcast Conference Call". Chemours announced it expects to release its third-quarter 2026 financial results after market close on Monday, November 2, 2026.
The Chemours Company is a global chemistry company that develops and supplies industrial and specialty chemical products for a wide range of end markets. Its core business is organized into Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials, each serving distinct applications across refrigeration and air conditioning, coatings, plastics, transportation, semiconductors, electronics, and general industrial uses. The company’s product portfolio includes refrigerants, thermal management solutions, propellants, blowing agents, specialty solvents, titanium dioxide pigments, and advanced fluoropolymer materials. These materials are used as key inputs in manufacturing and performance-driven applications, supporting customers that need durability, efficiency, brightness, opacity, and thermal control. Chemours serves a global customer base across North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa, making it an important supplier within the specialty chemicals market.
CEO Ms. Denise M. Dignam · 5,700 employees · United States · https://www.chemours.com
